CBIO reorganization is unduly complex, IMO: https://www.globenewswire.com/news-release/2022/12/27/2579778/0/en/Catalyst-Biosciences-Completes-First-Steps-in-Reverse-Merger-Plan.html If it takes multiple readings of the PR to (maybe) understand how the deal works, there’s a problem.